The effect and safety of single tablet of fixed dose mitiglinide and voglibose when changed from DPP-4 inhibitor

The effect and safety of single tablet of fixed dose mitiglinide and voglibose when changed from DPP-4 inhibitor - The effect and safety of single tablet of fixed dose mitiglinide and voglibose

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011148

Enrollment

Registered

2013-07-09

Start date

2012-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Administration of single tablet of fixed dose mitiglinide (10 mg) and voglibose (0.2 mg) Administration of DPP-4 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus whose HbA1c(NGSP) are more than 6.8% on DPP-4 inhibitor treatment more than 3 months.

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus Women who are or might be pregnant

Design outcomes

Primary

Measure	Time frame
8-OHdG, hs-CRP, HbA1c(NGSP), glycoalbumin, 1,5-AG	—

Secondary

Measure	Time frame
QOL of the patients	—

Countries

Japan

Contacts

Public ContactMasami Tanaka

School of Medicine, Keio University Department of Internal Medicine

tana176k@a7.keio.jp03-5363-3797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026